WANG, FUQUAN – Trademark Portfolio
Entity Type: 01
WANG, FUQUAN holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 14 filings in this category. The portfolio also extends into Class 25 (Clothing) across 4 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include IGEBIN, FESENBO, and SIMDIMY. The owner is based in BAIYUN DISTRICT GUANGZHOU, GUANGDONG.
JINGXI STREET, GUANGZHOU DADAO NORTH
BAIYUN DISTRICT GUANGZHOU, GUANGDONG , CN
Showing of trademarks Trademarks
Trademark Classifications
WANG, FUQUAN's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Precious metals and their alloys; jewellery, precious stones; horological instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does WANG, FUQUAN have?
WANG, FUQUAN has 17 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned, 13 cancelled.
What trademark classes does WANG, FUQUAN file in?
WANG, FUQUAN files trademarks across 4 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 25 (Clothing), Class 14 (Jewelry), Class 5 (Pharmaceuticals). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are WANG, FUQUAN's most well-known trademarks?
WANG, FUQUAN's registered trademark portfolio includes well-known marks such as IGEBIN, FESENBO, and SIMDIMY. These are among 3 currently registered trademarks in the portfolio.
What is WANG, FUQUAN's trademark registration success rate?
WANG, FUQUAN has a 18% trademark registration rate, with 3 out of 17 resolved applications resulting in successful registration. Currently, 0 applications are pending review.